查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985569

溶瘤病毒疗法市场：2026-2032年全球市场预测（按病毒类型、癌症适应症、给药途径和最终用户划分）

Oncolytic Virus Therapies Market by Virus Type, Cancer Indication, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，溶瘤病毒疗法市场价值将达到 1.5379 亿美元，到 2026 年将成长至 1.8498 亿美元，到 2032 年将达到 4.4483 亿美元，年复合成长率为 16.38%。

主要市场统计数据
基准年 2025 1.5379亿美元
预计年份：2026年 1.8498亿美元
预测年份 2032 4.4483亿美元
复合年增长率 (%) 16.38%

溶瘤病毒疗法的策略架构：聚焦转化潜力、生产实际情况、临床试验设计需求和生态系统驱动因素

溶瘤病毒疗法处于快速发展的病毒学、免疫肿瘤学和精准医学的交叉领域，它提供了一种全新的作用机制，能够选择性地感染和裂解癌细胞，同时刺激抗肿瘤免疫。该领域已从概念验证（PoC）临床试验发展到更为复杂的病毒基因组、有效载荷和递送系统设计，旨在扩大治疗范围并解决固态肿瘤靶向治疗的难题。随着研发进程的推进，相关人员必须权衡生物学复杂性与实际考量，例如可扩展的生产、低温运输物流以及对能够反映直接溶瘤效应和下游免疫介导反应的可靠临床终点的需求。

近期技术进步、联合治疗策略、生产技术的改进以及法规环境的变化如何重新定义溶瘤病毒的开发和商业化。

溶瘤病毒疗法的格局正在发生变化，重塑着竞争动态、临床开发策略和投资重点。病毒工程技术的进步使得整合能够调节肿瘤微环境、表达免疫刺激细胞激素或呈现肿瘤相关抗原以促进抗原扩散的有效载荷成为可能。这些技术变革，以及载体设计的改进，提高了肿瘤选择性并降低了脱靶亲和性，从而提高了治疗指数，并将潜在适应症扩展到除浅层病变以外的其他部位。

本研究评估了预计 2025 年美国关税和贸易政策变化对溶瘤病毒疗法的供应链、製造决策和共同开发模式的影响。

预计2025年的关税措施和贸易政策调整可能会对供应链、试剂采购和生技药品生产的成本结构产生连锁反应，并可能对溶瘤病毒研发者及其合作伙伴造成重大影响。病毒载体生产所需的许多关键材料，例如试剂、特殊塑胶、一次性生物反应器组件以及某些上游工程细胞培养基成分，均来自世界各地。进口关税的提高、海关处理时间的延长或边境检查的加强都可能导​​致活性成分和生产材料的前置作业时间延长，并推高总体成本。

一种基于精确细分的观点适应症的生物学特征、病毒平台的特征、给药途径和临床护理环境与可行的开发策略联繫起来。

基于细分的洞察揭示了不同适应症、病毒平台、给药途径和终端用户中存在的微妙机会和限制，从而影响临床策略和商业计划。就癌症适应症而言，由于血脑障壁和局部肿瘤异质性，胶质母细胞瘤的递送面临独特的挑战。另一方面，儘管头颈部癌症的免疫微环境复杂，但其瘤内注射部位相对容易取得；黑色素瘤则继续作为模型适应症，其皮肤病变便于直接给药和评估溶瘤活性。就病毒类型而言，基因改造病毒具有可设计有效载荷和安全开关等优势，而野生型病毒则具有固有的亲和性并能降低初始开发的复杂性。在基因改造平台中，腺病毒、单纯疱疹病毒和痘苗病毒各自具有不同的亲和性、有效载荷能力和安全性，需要根据每种适应症的特定生物学特征进行客製化。

从全面的区域观点检验法律规范、临床基础设施和生产能力如何影响全球主要市场肿瘤疗法的发展。

区域趋势在全球溶瘤病毒格局的形成中发挥核心作用，包括临床试验生态系统、製造地和监管合作。美洲受益于成熟的监管路径、广泛的临床试验网络以及来自创投和大型企业的巨额投资，但也面临着激烈的生产能力竞争和复杂的医保报销环境，这些都影响着商业化策略。欧洲和中东及非洲（EMEA）的监管环境各不相同，各国卫生技术评估（HTA）框架和临床基础设施差异较大，因此需要采取个人化的监管措施和市场准入策略。此外，跨欧洲的临床试验倡议和成熟的学术研究中心仍然是该地区转化科学发展的重要贡献来源。

企业策略行动、伙伴关係模式和製造投资，旨在建立竞争优势并实现肿瘤病毒专案的可扩展执行。

溶瘤病毒领域的企业正透过平台专业化、策略联盟以及对生产规模化和监管合规的投资来实现差异化竞争。一些企业专注于快速有效载荷更换和模组化工程方法，以简化跨多种肿瘤类型的临床应用；而另一些企业则强调在特定适应症中进行全面的生物学优化，以增强给药途径和肿瘤微环境的特征，从而提高溶瘤活性。早期研发公司与成熟的生物製药企业之间的策略联盟日益普遍，这有助于企业在无需完全内部垂直整合的情况下，获得符合GMP标准的生产能力、监管专业知识和商业管道。

为决策者提供整合策略指导，以协调转化科学、生产韧性、监管合作和市场进入计划，并降低与专案进度相关的风险。

产业领导者必须采用一套整合的策略，将科学策略、营运准备和市场进入计画相协调，以最大限度地提高转换和商业性成功的潜力。应优先开发稳健的生物标记和转化项目，以降低临床假设风险、实现适应性试验设计并支持监管咨询。同时，必须儘早投资于製程开发和供应商选择，以确保规模化生产时的可比性并最大限度地减少延误。在条件允许的情况下，应寻求与免疫肿瘤学领域的合作伙伴建立策略伙伴关係，以设计利用互补机制的合理联合治疗试验，并分担监管和商业化风险。

一个透明的、跨学科的研究框架，结合文献整合、专家咨询和情境分析，以检验策略见解和操作建议。

本分析的调查方法包括对同行评审文献、监管指导文件、临床试验註册数据以及公开的技术白皮书进行严格审查，以构建科学进展和运营趋势的全面视图。此外，与临床医生、生物製程工程师、监管专家和契约製造公司高管的系统性专家咨询，为供应策略、规模化挑战和供应链脆弱性提供了切实可行的见解。在整合证据时，优先考虑现有的原始资料和监管申报文件，并透过与独立专家意见和技术文件交叉核对来协调相互矛盾的数据。

简要概述了将溶瘤病毒研究转化为有意义的临床结果所需的科学可能性、操作挑战和合作途径。

溶瘤病毒疗法在免疫肿瘤学领域占据着一个极具吸引力的细分市场，它既融合了创新的生物学机制，也面临着特定的操作挑战。科学进步使得病毒工程和活性成分递送更加精准，但要将这些成果转化为临床和商业性的成功，需要对生产製造、供应链韧性和监管策略进行精心调整。根据适应症、病毒平台、给药途径和最终用户环境进行策略性细分，可以提供有针对性的临床开发和商业化路径，从而提升患者获益和企业投资回报。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：溶瘤病毒疗法市场（依病毒类型划分）

  • 基因改造病毒
    • 腺病毒
    • 单纯疱疹病毒
    • 牛痘病毒
  • 野生型病毒

第九章：溶瘤病毒疗法市场（以癌症适应症划分）

  • 胶质母细胞瘤
  • 头颈癌
  • 恶性黑色素瘤

第十章：溶瘤病毒疗法市场（依给药途径划分）

  • 肿瘤内部
  • 静脉

第十一章 溶瘤病毒疗法市场：以最终用户划分

  • 医院
  • 研究机构
  • 专科诊所

第十二章 溶瘤病毒疗法市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 溶瘤病毒疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 溶瘤病毒疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国溶瘤病毒疗法市场

第十六章：中国溶瘤病毒疗法市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd
Product Code: MRR-007C484E5E64

The Oncolytic Virus Therapies Market was valued at USD 153.79 million in 2025 and is projected to grow to USD 184.98 million in 2026, with a CAGR of 16.38%, reaching USD 444.83 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.79 million
Estimated Year [2026] USD 184.98 million
Forecast Year [2032] USD 444.83 million
CAGR (%) 16.38%

A strategic framing of oncolytic virus therapies highlighting translational promise, manufacturing realities, clinical design imperatives and ecosystem enablers

Oncolytic virus therapies represent a rapidly evolving intersection of virology, immuno-oncology, and precision medicine, offering a novel mechanism of action that selectively infects and lyses tumor cells while stimulating antitumor immunity. The field has matured from proof-of-concept clinical demonstrations to more sophisticated engineering of viral genomes, payloads, and delivery systems that aim to broaden therapeutic windows and address solid tumor accessibility challenges. As development pathways advance, stakeholders must reconcile biological complexity with practical considerations such as scalable manufacturing, cold-chain logistics, and the necessity of robust clinical endpoints that capture both direct oncolytic effects and downstream immune-mediated responses.

Translational success often hinges on the integration of preclinical mechanistic insight with pragmatic trial design. Iterative learning from early-phase studies has refined patient selection strategies, intratumoral and systemic dosing approaches, and combinatorial regimens with checkpoint inhibitors or other immunomodulators. Continued progress requires tight alignment between scientific innovation and regulatory engagement to establish meaningful safety monitoring frameworks and to validate biomarkers that predict response or resistance. Moreover, public and private research institutions, clinical trial networks, and specialized contract manufacturing organizations are forming the operational backbone that will determine the pace at which promising candidates can move from bench to larger cohort evaluation.

Looking forward, the trajectory of oncolytic virus therapies will depend not only on scientific breakthroughs but on the ecosystem's ability to scale manufacturing, secure supply chains for viral vectors and raw materials, and navigate evolving reimbursement and policy environments. Stakeholders that proactively address these translational and operational imperatives will be better positioned to convert biological potential into clinically actionable therapeutics.

How recent technological advances, combination therapy strategies, manufacturing improvements, and regulatory evolutions are redefining oncolytic virus development and commercialization

The landscape for oncolytic virus therapies is shifting in ways that reconfigure competitive dynamics, clinical development strategies, and investment priorities. Advances in viral engineering now enable the incorporation of payloads that modulate tumor microenvironments, express immune-stimulatory cytokines, or present tumor-associated antigens to enhance antigen spreading. These technological shifts are complemented by improved vector design to enhance tumor selectivity and to limit off-target tropism, thereby improving therapeutic indices and expanding potential indications beyond accessible superficial lesions.

Concurrently, clinical strategy is evolving from monotherapy proofs toward combination regimens where oncolytic agents act synergistically with immune checkpoint inhibitors, adoptive cell therapies, or targeted agents. This shift requires more complex trial designs and collaborative networks to test rational combinations and dose sequencing. On the operations side, improvements in GMP-compliant manufacturing and fill-finish processes are enabling higher-quality and more reproducible viral product batches, while emerging contract development and manufacturing partnerships are offloading capital intensity from smaller biotechs. Investor expectations are also changing: funders increasingly prioritize programs with clear biomarker strategies and manufacturability, favoring platforms that demonstrate scalability and regulatory engagement.

Finally, regulatory frameworks and payor dialogues are adapting to the unique attributes of oncolytic modalities, with agencies showing openness to innovative endpoints and adaptive trial schemas when supported by strong mechanistic rationale and safety data. Taken together, these transformative shifts are creating an environment where scientific novelty must be matched by operational maturity and strategic clinical collaborations to achieve durable commercial and patient impact.

Assessing how anticipated United States tariffs and trade policy shifts in 2025 could reshape supply chains, manufacturing decisions, and collaborative models for oncolytic therapies

Anticipated tariff measures and trade policy adjustments in 2025 are likely to have ripple effects on supply chains, reagent sourcing, and the cost structures of biologics manufacturing that materially influence oncolytic virus developers and their partners. Many critical inputs for viral vector production-including reagents, specialized plastics, single-use bioreactor components, and certain upstream cell culture media constituents-are sourced globally; any increase in import duties, customs processing times, or border checks can translate into longer lead times and higher landed costs for active pharmaceutical ingredients and manufacturing supplies.

Moreover, tariffs that alter the relative attractiveness of regional sourcing may accelerate reshoring or near-shoring strategies, prompting sponsors to reassess supplier portfolios and invest in redundant sourcing to mitigate disruption risk. This change can lead to short- and medium-term capital allocation toward local manufacturing capacity or in-country fill-finish services. In parallel, contract manufacturing organizations may pass through higher input costs to clients, affecting program budgets and potentially the timing of trial initiation. Regulatory compliance burdens can also be affected if tariff-driven supply chain modifications necessitate changes in supplier qualifications or material provenance documentation, requiring additional comparability assessments for biologics.

Trade policy shifts can also influence collaborative models. Cross-border academic-industry partnerships that rely on rapid exchange of biological materials and analytical services may face administrative friction if new customs or licensing requirements are introduced. Such constraints can slow translational timelines and raise the value of digital and remote collaborations, in silico modeling, and local clinical trial capacity. Finally, the cumulative impact of tariff changes will disproportionately affect early-stage developers and academic spin-outs with limited procurement scale, making strategic procurement planning and supplier diversification essential for program resilience.

Precision segmentation-driven perspectives that link indication biology, viral platform attributes, delivery routes, and clinical care settings to actionable development strategies

Segmentation-informed insights reveal nuanced opportunities and constraints across indications, viral platforms, administration routes, and end users that influence clinical strategy and commercial planning. When considering cancer indications, glioblastoma presents unique delivery challenges due to the blood-brain barrier and localized tumor heterogeneity, head and neck cancers offer relatively accessible intratumoral injection sites with complex immune microenvironments, and melanoma continues to serve as a model indication where cutaneous lesions facilitate direct administration and oncolytic activity assessment. In terms of virus type, genetically modified viruses bring the advantage of engineered payloads and safety switches, while wild type viruses can offer innate tropism and lower initial development complexity; within genetically modified platforms, adenovirus, herpes simplex virus, and vaccinia virus each offer distinct tissue tropisms, payload capacities, and safety profiles that must be aligned to indication-specific biology.

Administration route choices between intratumoral and intravenous approaches materially impact trial design, patient selection, and manufacturing specifications. Intratumoral administration enables high local viral titers and reduced systemic exposure but limits applicability to accessible lesions, whereas intravenous delivery offers the potential for treating disseminated disease but faces challenges of systemic neutralization, off-target sequestration, and altered biodistribution. End-user segmentation across hospitals, research institutes, and specialty clinics shapes commercial access pathways and service delivery models. Hospitals and specialized oncology centers offer integrated care and advanced interventional capabilities for intratumoral procedures, research institutes drive early translational studies and investigator-initiated trials, and specialty clinics can support routine administration workflows and patient monitoring for outpatient regimens.

Taken together, these segmentation elements underscore the importance of aligning viral platform selection, payload engineering, and delivery strategy to the biological and operational realities of each indication and care setting. Strategic decisions must balance the biological rationale with practical implementation constraints to optimize the pathway from clinical validation to scalable clinical use.

A comprehensive regional lens exploring how regulatory frameworks, clinical infrastructure, and manufacturing capabilities influence oncolytic therapy development across major global markets

Regional dynamics play a central role in shaping clinical trial ecosystems, manufacturing footprints, and regulatory interactions across the global oncolytic virus landscape. The Americas benefit from established regulatory pathways, extensive clinical trial networks, and deep venture and corporate investment but also face concentrated competition for manufacturing capacity and complex reimbursement environments that influence commercialization strategies. Europe, Middle East & Africa present diverse regulatory landscapes where country-specific health technology assessment frameworks and clinical infrastructure variability drive tailored regulatory and market-access approaches; collaborative pan-European trial initiatives and well-established academic centers continue to be important contributors to translational science in the region.

In Asia-Pacific, rapidly expanding clinical trial capacity, increasing biotech investment, and strategic government support for biotechnology infrastructure create fertile conditions for accelerated clinical development and local manufacturing expansion. Differences in patient demographics, prevalent cancer indications, and treatment paradigms across regions necessitate targeted clinical development strategies, and regional manufacturing hubs are becoming increasingly relevant as sponsors weigh the benefits of near-market production against tariff and logistics considerations. Cross-regional partnerships and localized regulatory engagement strategies are instrumental in navigating differences in trial endpoints, data requirements, and approval timelines.

Therefore, regional insight should inform not only where trials are conducted but how manufacturing, regulatory planning, and commercial strategies are orchestrated to maximize patient access and program resilience across disparate healthcare systems.

Strategic corporate behaviors, partnership models, and manufacturing investments that define competitive advantage and enable scalable oncolytic virus program execution

Companies operating in the oncolytic virus sector are differentiating through platform specialization, strategic collaborations, and investments in manufacturing scale-up and regulatory engagement. Some organizations are focusing on modular engineering approaches that enable rapid payload swaps and streamlined clinical translation across multiple tumor types, while others emphasize deep biological optimization for specific indications where delivery routes and tumor microenvironment characteristics favor oncolytic activity. Strategic collaborations between early-stage developers and established biologics manufacturers have become commonplace, facilitating access to GMP capacity, regulatory expertise, and commercial channels without necessitating full in-house vertical integration.

Investment patterns also show that firms prioritizing clear biomarker development programs and translational data tend to attract more strategic interest from partners seeking combination therapy opportunities. Contract development and manufacturing organizations are evolving their service offerings to include viral vector-specific process development, analytical method validation, and virus-specific comparability assessments, thereby lowering the barrier to clinical manufacturing for smaller companies. Additionally, licensing deals and codevelopment agreements frequently include provisions for phased milestones tied to clinical proof points, reflecting a pragmatic balance between risk-sharing and incentivizing accelerated development.

From a competitive perspective, companies that can demonstrate robust supply chain strategies, validated manufacturing platforms, and proactive regulatory interactions will be preferentially positioned to execute complex combination trials and to secure sustainable commercial pathways. Organizational agility in responding to clinical learnings and in pivoting platform applications remains a core differentiator in a field where scientific understanding and operational demands evolve rapidly.

An integrated strategic playbook for decision-makers that aligns translational science, manufacturing resilience, regulatory engagement, and market access planning to de-risk program progression

Industry leaders should adopt an integrated playbook that aligns scientific strategy with operational readiness and market access planning to maximize the probability of translational and commercial success. Prioritize the development of robust biomarker and translational programs that can de-risk clinical hypotheses, enable adaptive trial designs, and support regulatory discussions; simultaneously, invest early in process development and vendor qualification to ensure comparability and minimize delays during scale-up. Where feasible, pursue strategic collaborations with immuno-oncology partners to design rational combination studies that leverage complementary mechanisms and to share regulatory and commercialization risk.

Operationally, build redundant supply chains and establish relationships with multiple qualified suppliers and contract manufacturers to mitigate tariff-related and logistical disruptions. Tailor clinical development pathways to indication- and region-specific realities, selecting administration routes and endpoints that optimize signal detection and patient enrollment feasibility. Engage payors and health technology assessment bodies early to understand evidence expectations and to design health-economic data collection approaches that support future reimbursement discussions. Finally, maintain active regulatory dialogue to clarify expectations around safety monitoring, manufacturing comparability, and accelerated approval pathways where appropriate, translating scientific momentum into durable patient access.

A transparent, multidisciplinary research framework combining literature synthesis, expert consultations, and scenario analysis to validate strategic insights and operational recommendations

The research methodology underpinning this analysis combined a rigorous review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical white papers to construct a holistic view of scientific progress and operational trends. In addition, structured expert consultations with clinicians, bioprocess engineers, regulatory affairs specialists, and contract manufacturing executives informed practical considerations around delivery strategies, scale-up challenges, and supply chain vulnerabilities. Evidence synthesis prioritized primary sources and regulatory filings where available, and conflicting data points were reconciled through triangulation across independent expert perspectives and technical documentation.

Analytical approaches included qualitative thematic analysis of translational challenges, operational gap mapping to identify bottlenecks in manufacturing and logistics, and scenario-based assessment of policy impacts on supply chains and collaborative models. Ethical standards guided the selection and interpretation of clinical data, with careful attention paid to safety signals, patient population heterogeneity, and endpoint relevance. Finally, recommendations were stress-tested against real-world operational constraints to ensure that proposed actions are implementable within typical development timelines and resource envelopes.

A concise synthesis emphasizing the scientific promise, operational imperatives, and collaborative pathways necessary to translate oncolytic virus research into meaningful clinical impact

Oncolytic virus therapies occupy a compelling niche within the broader immuno-oncology landscape, balancing innovative biological mechanisms with tangible operational challenges. The science has progressed to enable more precise viral engineering and payload delivery, but translation to clinical and commercial success requires careful orchestration of manufacturing, supply chain resilience, and regulatory strategy. Strategic segmentation by indication, virus platform, administration route, and end-user setting informs targeted clinical development and commercialization pathways that improve the likelihood of patient benefit and organizational return on investment.

Policymakers and industry stakeholders must remain attentive to external factors such as trade policy and regional manufacturing dynamics that can influence program timelines and cost structures. By adopting integrated development strategies that pair scientific rigor with operational foresight, organizations can better navigate the complexity inherent in bringing oncolytic therapies from concept to clinic. Continued collaboration across academic centers, industry partners, contract manufacturers, and regulators will be essential to realize the full potential of oncolytic modalities for patients with hard-to-treat cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncolytic Virus Therapies Market, by Virus Type

  • 8.1. Genetically Modified Virus
    • 8.1.1. Adenovirus
    • 8.1.2. Herpes Simplex Virus
    • 8.1.3. Vaccinia Virus
  • 8.2. Wild Type Virus

9. Oncolytic Virus Therapies Market, by Cancer Indication

  • 9.1. Glioblastoma
  • 9.2. Head And Neck Cancer
  • 9.3. Melanoma

10. Oncolytic Virus Therapies Market, by Administration Route

  • 10.1. Intratumoral
  • 10.2. Intravenous

11. Oncolytic Virus Therapies Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Oncolytic Virus Therapies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncolytic Virus Therapies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncolytic Virus Therapies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oncolytic Virus Therapies Market

16. China Oncolytic Virus Therapies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amunbio Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. BioInvent International AB
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Calidi Biotherapeutics, Inc.
  • 17.11. Candel Therapeutics
  • 17.12. Daiichi Sankyo Company Ltd.
  • 17.13. Elicera Therapeutics AB
  • 17.14. EpicentRx, Inc.
  • 17.15. Genelux Corporation
  • 17.16. Hookipa Pharma Inc.
  • 17.17. Imvaq Therapeutics
  • 17.18. Istari Oncology, Inc.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lokon Pharma AB
  • 17.21. Merck & Co., Inc.
  • 17.22. Orgenesis Inc.
  • 17.23. Pfizer, Inc.
  • 17.24. Protheragen Inc.
  • 17.25. Seneca Therapeutics, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. TILT Biotherapeutics
  • 17.28. Treovir LLC
  • 17.29. Wuhan Binhui Biotechnology Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 105. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 123. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 129. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)